The University of Oxford has discontinued COVID-19 vaccine doses that it developed with AstraZeneca PLC AZN,
AZN,
in a small UK study to assess its safety and effectiveness in children and adolescents, to wait for more information on the rare blood clotting problems found in a small group of adults who received it, reported Tuesday the Wall Street Journal. The trial began in mid-February and involves more than 200 young people between the ages of 6 and 17, the newspaper said. He quoted an Oxford spokesman as saying that the process had not found any safety issues, but that wider concerns and a review of the vaccine by regulators in the UK and the European Union were behind the move. The European Medicines Agency said earlier that it expects to update the public on its investigation into the problem of blood clotting later this week.